Knights of Columbus Asset Advisors LLC Lowers Stake in Cencora, Inc. $COR

Knights of Columbus Asset Advisors LLC cut its position in Cencora, Inc. (NYSE:COR) by 7.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 42,225 shares of the company’s stock after selling 3,638 shares during the period. Cencora makes up about 0.8% of Knights of Columbus Asset Advisors LLC’s investment portfolio, making the stock its 22nd largest holding. Knights of Columbus Asset Advisors LLC’s holdings in Cencora were worth $14,261,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Vestcor Inc lifted its position in shares of Cencora by 0.5% during the 3rd quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after acquiring an additional 28 shares during the period. JFS Wealth Advisors LLC lifted its position in shares of Cencora by 30.2% during the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after acquiring an additional 29 shares during the period. Apollon Wealth Management LLC lifted its position in shares of Cencora by 0.5% during the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after acquiring an additional 30 shares during the period. Accent Capital Management LLC lifted its position in shares of Cencora by 36.1% during the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after acquiring an additional 30 shares during the period. Finally, CYBER HORNET ETFs LLC lifted its position in shares of Cencora by 6.8% during the 4th quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock valued at $164,000 after acquiring an additional 31 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

Cencora stock opened at $271.84 on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The company has a market capitalization of $52.89 billion, a PE ratio of 20.85, a P/E/G ratio of 1.27 and a beta of 0.64. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a 50-day moving average price of $302.59 and a two-hundred day moving average price of $335.67.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Cencora declared that its board has approved a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on COR shares. Wells Fargo & Company dropped their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. UBS Group upped their price objective on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. William Blair started coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating for the company. Robert W. Baird dropped their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a research report on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.